文献速递治疗药物监测与药物基因组学

真实世界队列中恩扎卢胺及其主要代谢物的暴露-反应评估

Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · Pharmacotherapy · 2019-11-05

该回顾性药代动力学研究纳入65例接受恩扎卢胺160 mg/d治疗的mCRPC患者,比较PSA应答者与非应答者的血浆浓度,发现恩扎卢胺及其主要代谢物浓度与PSA无进展生存、至PSA进展时间及毒性均无关,提示日常实践无需进行治疗药物监测。

要点

  • 恩扎卢胺及其代谢物血浆浓度与PSA应答、PFS、TTPP及毒性均无显著关联。
  • PSA应答者与非应答者的恩扎卢胺浓度差异无统计学意义(11.5 vs 10.6 μg/ml,p=0.20)。
  • 基于现有证据,mCRPC患者日常实践不推荐对恩扎卢胺进行治疗药物监测。

核心结论

  • 恩扎卢胺血浆浓度与PSA无进展生存、至PSA进展时间及毒性无关,其主要代谢物浓度亦与治疗反应无关。
  • 基于上述发现,mCRPC患者日常实践无需对恩扎卢胺进行治疗药物监测。

研究设计与样本

  • 回顾性观察性药代动力学研究,纳入65例接受恩扎卢胺160 mg每日一次治疗的mCRPC患者,其中PSA应答者38例、非应答者27例。
  • 患者至少有一次稳态恩扎卢胺血浆浓度,采血时间范围为2015年5月至2018年6月,地点为荷兰阿姆斯特丹某三级癌症中心门诊。

主要发现

  • 65例患者恩扎卢胺平均血浆浓度为11.2 ± 2.8 μg/ml,N-去甲基恩扎卢胺为9.9 ± 2.9 μg/ml,羧酸恩扎卢胺为6.1 ± 4.3 μg/ml。
  • PSA应答者与非应答者的恩扎卢胺浓度分别为11.5 vs 10.6 μg/ml(p=0.20),N-去甲基恩扎卢胺为10.1 vs 9.6 μg/ml(p=0.48),羧酸恩扎卢胺为6.5 vs 5.5 μg/ml(p=0.34),差异均无统计学意义。
  • 单变量和多变量分析均未显示血浆浓度与PSA无进展生存、至PSA进展时间或毒性之间存在关系。

关键数值与推荐

  • PSA应答定义为PSA水平较基线下降≥50%。
  • 毒性定义为因不良事件停药、因不良事件减量或暂时中断治疗。
  • 血浆浓度采用液相色谱-串联质谱法测定,并按四分位数分组分析。

临床怎么用

  • 基于该研究结果,mCRPC患者日常实践中无需对恩扎卢胺进行治疗药物监测。
  • 恩扎卢胺及其主要代谢物的血浆浓度不宜作为预测PSA应答、疾病进展或毒性的常规指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Enzalutamide is an oral agent for the treatment of metastatic castration-resistant prostate cancer (mCRPC); N-desmethyl enzalutamide is its active metabolite, which has clinically relevant anti-androgen capacities similar to enzalutamide, and carboxylic acid enzalutamide is an inactive metabolite. The aim of our study was to investigate the relationship between enzalutamide and N-desmethyl enzalutamide exposure and treatment response in a real-world cohort of patients with mCRPC. DESIGN: Retrospective, observational, pharmacokinetic study. SETTING: Outpatient clinic at a tertiary cancer center in Amsterdam, the Netherlands. PATIENTS: Sixty-five patients with mCRPC who were treated with enzalutamide 160 mg daily and had at least one steady-state enzalutamide plasma concentration between May 2015 and June 2018; of these patients, 38 were prostate-specific antigen (PSA) responders and 27 were nonresponders. MEASUREMENTS AND MAIN RESULTS: Plasma concentrations, determined by using liquid chromatography with tandem mass spectrometry (LC-MS/MS), were compared between PSA responders and nonresponders. Three clinical end points were evaluated separately in this study: PSA-independent progression-free survival (PFS), time to PSA progression (TTPP), and rate of PSA response (defined as ≥ 50% decrease in PSA level from baseline). Enzalutamide toxicity was defined as discontinuation due to adverse events, dose reductions due to adverse events, or temporary treatment interruption. For these analyses, plasma concentrations of enzalutamide and N-desmethyl enzalutamide were divided into quartiles. Mean ± SD plasma concentrations in the 65 patients were as follows: enzalutamide 11.2 ± 2.8 μg/ml, N-desmethyl enzalutamide 9.9 ± 2.9 μg/ml, and carboxylic acid enzalutamide 6.1 ± 4.3 μg/ml. Plasma concentrations were not significantly different in the PSA responder versus nonresponder groups for enzalutamide (11.5 vs 10.6 μg/ml, p=0.20), N-desmethyl enzalutamide (10.1 vs 9.6 μg/ml, p=0.48), and carboxylic acid enzalutamide (6.5 vs 5.5 μg/ml, p=0.34). Univariate and multivariate analyses did not show a relationship between plasma concentrations and PSA-independent PFS, TTPP, or toxicity. CONCLUSION: This study confirmed that enzalutamide plasma concentrations were not related to PSA-independent PFS, TTPP, or toxicity in patients with mCRPC, and demonstrated that plasma concentrations of its major metabolites were also not associated with treatment response. Based on these findings, there is no role for therapeutic drug monitoring of enzalutamide in patients with mCRPC in daily practice.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. van Nuland M, Bergman AM, Rosing H, et al. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer. Pharmacotherapy. 2019. PMID: 31596947. doi:10.1002/phar.2339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。